HBV Infection and Chronic Hepatitis B

Sharifu LM^1*, Kibaba P², Jun Y¹, Yu Z¹, Jingyi Z¹, Er-jiao S¹, Rong L¹, Shaoshuai W¹ and Ling F¹

¹Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan 4300030, China

²Department of Molecular Virology, Wuhan institute of Virology, Wuhan 4300030, China

*Corresponding Author : Lali Mwamaka Sharifu
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan 4300030, China
Tel: +86 27 6889 3313
E-mail: 1146114929@qq.com

Received: November 19, 2018 Accepted: December 05, 2018 Published: December 12, 2018

Citation: Sharifu LM, Kibaba P , Jun Y, Yu Z , Jingyi Z, et al. (2018) HBV Infection and Chronic Hepatitis B. J Liver Disease Transplant 7:2. doi: 10.4172/2325-9612.1000166

Hepatitis B virus (HBV) is a hepatotropic virus and one of the leading causes by both persistent and chronic infection of hepatitis B in human globally, more over China is a high population was affected by HBV. Currently ETV, TDF, and INF are recommended as a first-line treatment; however, many HBV positive patients will progress to a late stage with diseases such as, chronic hepatitis B cirrhosis and hepatocellular carcinoma (HCC). The uses of pegylated interferon-alpha for 48 weeks have led to a long-term control of HBV, but occasionally treatment failure is observed in a maximum no of patients. Prolonged use of NAs has proofed to suppress the virus, though safety and efficacy is not yet clarified, NAs unable clear the virus from infected cells, suggesting that the disease progression may not be stopped and the risk of development of significant complications is not yet eliminated. Novel treatment strategies are required.